Register to chat with like-minded investors on our interactive forums.
Period:
Draw Mode:
| Volume | 25,075 |
|
|||||
| News | - | ||||||
| Day High | 3.6546 | Low High |
|||||
| Day Low | 3.28 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Alimera Sciences Inc | ALIM | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.32 | -8.82% | 3.31 | 16:30:00 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 3.6546 | 3.28 | 3.6546 | 3.31 | 3.63 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 331 | 25,075 | $ 3.43 | $ 85,910 | - | 1.56 - 4.40 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 16:00:04 | 668 | $ 3.31 | USD |
Alimera Sciences Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 171.72M | 52.35M | - | 80.75M | -21.39M | -0.41 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Alimera Sciences News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ALIM Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 3.55 | 3.70 | 3.26 | 3.45 | 30,937 | -0.24 | -6.76% |
| 1 Month | 3.90 | 4.01 | 3.26 | 3.77 | 52,237 | -0.59 | -15.13% |
| 3 Months | 3.63 | 4.40 | 3.07 | 3.75 | 75,539 | -0.32 | -8.82% |
| 6 Months | 3.15 | 4.40 | 2.88 | 3.78 | 79,042 | 0.16 | 5.08% |
| 1 Year | 2.06 | 4.40 | 1.56 | 2.77 | 207,388 | 1.25 | 60.68% |
| 3 Years | 10.70 | 11.4799 | 1.30 | 3.35 | 89,834 | -7.39 | -69.07% |
| 5 Years | 0.88 | 12.25 | 0.0003 | 2.85 | 107,806 | 2.43 | 276.14% |
Alimera Sciences Description
| Alimera Sciences is a pharmaceutical company focused on commercializing and developing treatments that address diseases affecting the back of the eye (retina). ILUVIEN(R) is Alimera's a patented micro-implant which delivers a continuous, low dose anti-inflammatory agent to the retina for up to 3 years. A $2B global market, DME is often treated with acute therapies when the fluid in the eye returns. ILUVIEN reduces the recurrence of edema leading to stable vision, with the benefit of continuous treatment due to the product's novel drug delivery technology. |
